NCT05746208View on ClinicalTrials.gov

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

July 31, 2027

Study Completion Date

October 31, 2027

Conditions
Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site
Interventions
DRUG

Lenvatinib

Given orally

DRUG

Pembrolizumab

Given IV

DRUG

Hyperpolarized 13C-Pyruvate

Given IV

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT05746208 - Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter